BAL C-tail drug delivery molecules
First Claim
1. A method for delivering a therapeutic composition comprising:
- orally administering to an individual in need thereof a therapeutically effective amount of a C-tail protein conjugated to a therapeutic composition, in combination with a pharmaceutical carrier acceptable for oral administration,wherein the C-tail protein comprises at least four eleven amino acid repeats having at least three prolines present in the carboxy terminal region of human bile salt lipase as shown in Sequence ID No. 1 that binds to a specific receptor on intestinal cells.
1 Assignment
0 Petitions
Accused Products
Abstract
Drug delivery conjugates of including a BAL C-tail peptide including all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL) conjugated to a biologically active substance are described. The C-tail peptide-drug conjugates, when orally ingested, compete with native BAL in binding to the intestinal surface, and, as a result, permit drug compositions to be delivered specifically to the intestine. Useful C-tail peptides are derivatives of the carboxy terminal region of BAL derived from all or portion of the region containing amino acid residues 539 to 722, and have a mucin-like structure containing at least three of the repeating proline-rich units of eleven amino acid residues each.
-
Citations
29 Claims
-
1. A method for delivering a therapeutic composition comprising:
-
orally administering to an individual in need thereof a therapeutically effective amount of a C-tail protein conjugated to a therapeutic composition, in combination with a pharmaceutical carrier acceptable for oral administration, wherein the C-tail protein comprises at least four eleven amino acid repeats having at least three prolines present in the carboxy terminal region of human bile salt lipase as shown in Sequence ID No. 1 that binds to a specific receptor on intestinal cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)
-
-
14. A composition for delivering a therapeutic composition comprising:
-
a therapeutically effective amount of a C-tail protein conjugated to a therapeutic composition, in combination with a pharmaceutical carrier acceptable for oral administration, wherein the C-tail protein comprises at least four eleven amino acid repeats having at least three prolines present in the carboxy terminal region of human bile salt lipase as shown in Sequence ID No. 1, that binds to a specific receptor on intestinal cells. - View Dependent Claims (15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification